Johnson and Johnson touts new drugs

May 27, 2005 at 11:34 AM

NEW BRUNSWICK, N.J., May 27 (UPI) -- New Jersey's Johnson & Johnson says it has 17 new medicines in advanced stages of clinical testing or awaiting regulatory approval.

That's a big improvement of the last such report, in 2001, when the company said it had only two drugs at the same stage of development, the Wall Street Journal reported Friday.

The drugmaker attributes its improved output to improved research productivity, a slew of acquisitions and aggressive licensing. The experimental drugs treat illnesses that include the AIDS virus and various cancers.

Other prospects include dapoxetine, a pill for premature ejaculation; paliperidone, an antipsychotic related to Risperdal; and Yondelis, for soft-tissue sarcoma.

Like Us on Facebook for more stories from UPI.com  
Latest Headlines
Top Stories
Compact cannon for British armored vehicles
Volvo unveils new child seat concept
New Zealand military receives medium heavy military trucks
BBC to lay off 1,000 people to make up for $234M in lost revenue
U.S. proposes tighter pipeline spill rules